Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q4 FY20 Earnings Presentation
21 slides from Aurobindo Pharma's earnings presentation, Jun 3, 2020
Slide 1: Letter to stock exchanges: Investor/Analysts presentation
AUROBINDO June 3,2020 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI ·400 051 25th floor, Dalal Street, MUMBAI ·400 001 Company_Code No. AUROPHARMA Co
Slide 2: Aurobindo Pharma Limited Q4FY20 & FY20 Earnings Presentation
Aurobindo Pharma Limited Q4FY20 & FY20 Earnings Presentation 3rd June 2020
Slide 3: Disclaimer
Aurobindo Pharma Limited – Earnings Presentation 2 Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of
Slide 4: Index
Aurobindo Pharma Limited – Earnings Presentation 3 Index 1 Q4FY20 & FY20 Financial & Business Highlights 2 Financial Performance 3 Filings Snapshot
Slide 5: Q4FY20 & FY20 Financial & Business Highlights
1 Q4FY20 & FY20 Financial & Business Highlights 4
Slide 6: Consolidated Financial & Business Highlights – FY20
Aurobindo Pharma Limited – Earnings Presentation 5 Consolidated Financial & Business Highlights – FY20 In Rs Cr Revenue EBITDA Profit After Tax 18.1% 23.1% 19.7% 23,099 4,864 2,831 3,952 2,365 19,564 20.2% 21.1% FY19 FY20 FY19 FY20 FY19 FY20 EBITDA Margin
Slide 7: Consolidated Financial & Business Highlights – FY20
Aurobindo Pharma Limited – Earnings Presentation 6 Consolidated Financial & Business Highlights – FY20 Revenue from operations at Rs. 23,098.5 crore, witnessed a strong growth of 18.1% YoY EBIDTA before Forex and Other income at Rs. 4,864.3 crore, an increase of 23.1% YoY; EBITDA margin is at 21.1%
Slide 8: Consolidated Financial & Business Highlights – Q4FY20
Aurobindo Pharma Limited – Earnings Presentation 7 Consolidated Financial & Business Highlights – Q4FY20 In Rs Cr Revenue EBITDA Profit After Tax 16.4% YoY 26.6% YoY 45.2% YoY 4.5% QoQ 11.1% QoQ 20.5% QoQ 1,342 850 6,158 1,208 5,895 1,060 705 585 5,292 20.0% 20.5% 21.8% Q4FY19 Q3FY20 Q4FY20 Q4FY19 Q
Slide 9: Consolidated Financial & Business Highlights – Q4FY20
Aurobindo Pharma Limited – Earnings Presentation 8 Consolidated Financial & Business Highlights – Q4FY20 Revenue from operations at Rs. 6,158.4 crore, witnessed a strong growth of 16.4% YoY EBIDTA before Forex and Other income at Rs. 1,342.4 crore, an increase of 26.6% YoY; EBITDA margin is at 21.8%
Slide 10: Consistent Quarterly Performance
Aurobindo Pharma Limited – Earnings Presentation 9 Consistent Quarterly Performance Revenue ($ Mn) US Revenue ($ Mn) 831 851 404 418 413 753 783 797 387 733 353 635 679 318 339 630 271 282 Q4FY18 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 Q2FY20 Q3FY20 Q4FY20 Q4FY18 Q1FY19 Q2FY19 Q3FY19 Q4FY19 Q1FY20 Q2FY20
Slide 11: US Business Performance Highlights
Aurobindo Pharma Limited – Earnings Presentation 10 US Business Performance Highlights In Rs Cr Revenue Revenue Mix FY20 2,969 2,990 Orals Injectables* 64.1% 2,481 17.1% Total Injectables 23% Branded Oncology 6.2% Dietary Supplements Q4FY19 Q3FY20 Q4FY20 OTC 9.7% US Formulations 3.0% • US revenue fo
Slide 12: EU, ARV, Growth Markets, API Business Performance Highlights
Aurobindo Pharma Limited – Earnings Presentation 11 EU, ARV, Growth Markets, API Business Performance Highlights In Rs Cr EU Revenues Growth Markets Revenues ARV Revenues API Revenues 1,653 377 917 382 1,476 790 346 313 756 292 1,312 289 Q4FY19 Q3FY20 Q4FY20 Q4FY19 Q3FY20 Q4FY20 Q4FY19 Q3FY20 Q4FY20
Slide 13: Financial Performance
2 Financial Performance 12
Slide 14: Consolidated Financial Performance
Aurobindo Pharma Limited – Earnings Presentation 13 Consolidated Financial Performance Rs Cr Q4FY20 Q4FY19 (%) Chg Q3FY20 (%) Chg FY20 FY19 % Chg Revenue from operations 6,158.4 5,292.2 16.4 5,895.0 4.5 23,098.5 19,563.6 18.1 Gross Profit 3,655.1 2,919.6 25.2 3,330.0 9.8 13,363.3 10,850.9 23.2 Gross
Slide 15: Debt Profile
Aurobindo Pharma Limited – Earnings Presentation 14 Debt Profile Fx Loan US$ Mn Debt as on (Rs Crore) Mar-18 Mar-19 Sep-19 Dec-19 Mar-20 Closing Rate1 US$ = INR 65.17 69.155 70.875 71.385 75.6650 731 1,006 828 757 733 Fx Loan restated in INR 4,766.9 6,959.0 5,866.8 5,403.2 5,549.2 Rupee Loan 4.1 8.1
Slide 16: Key Ratios
Aurobindo Pharma Limited – Earnings Presentation 15 Key Ratios Gross Profit Margin (%) EBITDA Margin (%) Net Profit Margin (%) Earnings Per Share (Rs.) 57.9 21.1 48.32 55.5 12.1 12.3 20.2 40.36 FY19 FY20 FY19 FY20 FY19 FY20 FY19 FY20 Avg. RoE (%) Avg. RoCE (%)* Net Debt / EBITDA (x) Net Debt / Equit
Slide 17: Financial Performance – 5 Year trend
Aurobindo Pharma Limited – Earnings Presentation 16 Financial Performance – 5 Year trend Rs. Crore FY16 FY17 FY18 FY19 FY20 Revenue 13,955 15,090 16,500 19,564 23,099 Gross Profit 7,793 8,656 9,747 10,851 13,363 Gross Profit Margin 55.8% 57.4% 59.1% 55.5% 57.9% EBITDA 3,188 3,434 3,789 3,952 4,864 E
Slide 18: Filings Snapshot
3 Filings Snapshot 17
Slide 19: US Filings Snapshot as on 31st Mar 2020
Aurobindo Pharma Limited – Earnings Presentation 18 US Filings Snapshot as on 31st Mar 2020 Dermatology, Nasals and Opthalmic ANDA Filings Addressable Includes ANDAs of Orals, OTC, 397 Therapy ANDAs Market Size 324 73 (US$ Bn) 58 CNS 98 23.8 Non - Injectables Injectables CVS 89 27.8 161 131 ARV** 41
Slide 20: Filing details
Aurobindo Pharma Limited – Earnings Presentation 19 Filing details As at As at As at As at As at As at As at Category Approvals Mar 14 Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Formulations US* 336 376 398 429 478 541 586 425 (FA: 397, TA:28) 2,585 Dossiers (284 Europe** 1,542 1,756 2,224 2,521 2,84
Slide 21: Thank You
Thank You Investors Contact Investor Relations team ir@aurobindo.com 040-66725401